Journal ArticleOPEN ACCESS

PD-1 Axis Inhibitors in EGFR-and ALK-Driven Lung Cancer: Lost Cause?

Clinical Cancer Research (2016) 22(18) 4539-4541
DOI: 10.1158/1078-0432.CCR-16-1401
41Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

Abstract

Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 4539-41.

Cite

CITATION STYLE

APA

Gettinger, S., & Politi, K. (2016). PD-1 Axis Inhibitors in EGFR-and ALK-Driven Lung Cancer: Lost Cause? Clinical Cancer Research, 22(18), 4539–4541. https://doi.org/10.1158/1078-0432.CCR-16-1401

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free